German patent law as a system of reasonI had the chance to receive, ahead of publication, a copy of Pharmaceutical, Biological and Chemical Patents by Marco Stief, Maximilian Haedicke, and Annelie…
AI is driving innovation in every single industry. Particularly health care is facing unprecedented automation in its ecosystem from care management to real time inputs from medical literature. The…
Coinciding with the 100th year anniversary of the German and UK national groups of AIPPI, the GRUR Annual Meeting in Berlin hosted an “AIPPI Special” on 16 October 2025 to discuss the state of play…
The basic patent and SPC on Stelara®, the successful blockbuster drug of Janssen, have expired, which means that the generic producer Samsung Bioepis can potentially bring its generic drug on the…
Remember the days of old? The burning days of Brexit. When the UK decided to withdraw from the EU and the UPC system. When UK Judges would not become UPC judges. When Milan replaced London as a…
Preliminary injunctions (“PIs”) matter in life sciences patent cases. As often as not, the party which prevails at this stage of the litigation will have the upper hand in settlement…
The Russian Intellectual Property Court (IPC) recently revoked an extension (SPC) of Pfizer's Eurasian patent No. 012666 relating to the composition of tofacitinib in relation to the Russian…
In Du Hast, But Not So Fast, I suggested that the apparent hegemony of a few UPC divisions would in time recede under the pressure of practice and appellate calibration. The plot seems to be moving…
In patent law, the concept of “prior art” or “state of the art” describes the universe of information which existed and was made available to the public by means of a written or oral description, by…
T 1913/21 has received attention for nicely illustrating the difference between process claims and second non-medical use claims —a category of claims shaped by landmark Enlarged Board decisions G 2/…
